BHC
Bausch Health Companies Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +7.1% ·
share flow -5.7% ·
net new positions +6.7%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | +1 | 23.09K | $136,839 | +1 | n/a |
| Q2 2026 | 79 | -5 | 75.61M | $382.82M | +3 | −8 |
| Q1 2026 | 85 | -6 | 79.75M | $438.97M | +2 | −9 |
| Q4 2025 | 92 | +1 | 89.74M | $627.51M | +2 | n/a |
| Q3 2025 | 19 | +1 | 25.30M | $166.30M | +2 | −2 |
| Q2 2025 | 16 | -1 | 54.52M | $364.89M | n/a | −1 |
| Q1 2025 | 15 | +1 | 47.24M | $307.27M | +2 | −1 |
| Q4 2024 | 14 | +1 | 50.10M | $405.72M | +1 | n/a |
| Q3 2024 | 13 | +1 | 47.82M | $391.50M | +2 | −1 |
| Q2 2024 | 12 | n/a | 55.66M | $388.80M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Icahn Capital ✦ | 34.72M | 0.0% | $224.65M | 3.0% | Held | 4 | SEC ↗ |
| 2 | Arrowstreet Capital ✦ | 4.32M | -9.4% | $28.03M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | Oaktree Capital Management ✦ | 1.27M | 0.0% | $8.22M | 0.2% | Held | 4 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 1.26M | -75.8% | $8.14M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | GAMCO Investors ✦ | 1.04M | -3.0% | $6.75M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 755.53K | +5.6% | $6.48M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | Renaissance Technologies ✦ | 909.57K | +83.7% | $5.88M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Bridgewater Associates ✦ | 808.98K | +61.2% | $5.23M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Marshall Wace ✦ | 727.01K | New | $4.70M | 0.0% | New | 1 | SEC ↗ ×2 |
| 10 | D. E. Shaw & Co. ✦ | 547.88K | +0.6% | $3.55M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 11 | Millennium Management ✦ | 425.86K | -4.0% | $2.76M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 243.29K | -8.3% | $1.57M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | Gotham Asset Management ✦ | 102.44K | +54.9% | $662,800 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 83.69K | New | $541,500 | 0.0% | New | 1 | SEC ↗ |
| 15 | Norges Bank ✦ (passive) | 17.52K | 0.0% | $113,329 | 0.0% | Held | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $4.70M | 0.0% |
| Point72 Asset Management | $541,500 | 0.0% |
Exited
| Elliott Investment Management | $92,690 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 224 holders, 232.19M shares, $1.23B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 36.83K sh · $258,894
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology